Abstract
Variants in GBA1 are important genetic risk factors in Parkinson’s disease (PD). GBA1 T369M has been linked to an ∼80% increased PD risk but the reports are conflicting and the relevance of GBA1 variants in different populations varies. A lack of association between T369M and PD in the Swedish population was recently reported but needs further validation. We therefore investigated T369M in 1,808 PD patients and 2,183 controls and our results support that T369M is not a risk factor for PD in the Swedish population.
Competing Interest Statement
Co-author Oskar Hansson has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, C2N Diagnostics, Eli Lilly, Eisai, Fujirebio, GE Healthcare, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Alzpath, BioArctic, Biogen, Bristol Meyer Squibb, Cerveau, Eisai, Eli Lilly, Fujirebio, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens.
Funding Statement
K.A.B is supported by an employment contract with Queen Mary University of London (QMUL) to collaborate on the Global Parkinson's Genetics Program (GP2). O.H. was supported [OH1] by the National Institute of Aging (R01AG083740), European Research Council (ADG-101096455), Alzheimer's Association (ZEN24-1069572, SG-23-1061717), GHR Foundation, Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), Knut and Alice Wallenberg foundation (2022-0231), Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, Swedish Alzheimer Foundation (AF-980907), Swedish Brain Foundation (FO2021-0293), Parkinson foundation of Sweden (1412/22), Cure Alzheimer's fund, Ronstrom Family Foundation, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2022-1259) and Swedish federal government under the ALF agreement (2022-Projekt0080). AP receives research support from Region Skane, Parkinsonfonden, ALF, Hans Gabriel och Alice Trolle-Wachtmeister Foundation, Skane University Hospital and The Swedish Parkinson Academy.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The regional ethics review board of Lund, Sweden gave ethical approval for this work (2013/509 and 2006/615) The regional ethics review board of Umea, Sweden gave ethical approval for this work (03-387, 2014-163-31M, 2020-04074, 2021-03965, 2022-01219-01) The Swedish Ethical Review Authority gave ethical approval for this work(2022-03840-01 and 2019-05036). All participants gave informed written consent at study enrollment in each of the datasets.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting the findings of this study from the individual datasets are available upon reasonable request from the corresponding author or co-authors. The EpiHealth Elderly cohort is available for researchers following application and approval. The data for all datasets are not publicly available due to privacy or ethical restrictions. Frequency data for SweGen are openly available in the SweGen Variant Frequency Dataset at https://swefreq.nbis.se/.
